Tenecteplase is a Recombinant Enzyme owned by Genentech USA, and is involved in 33 clinical trials, of which 19 were completed, 11 are ongoing, and 3 are planned.
Tenecteplase (RG-3625) is a recombinant fibrin-specific plasminogen activator that is derived from native tissue plasminogen activator (tPA) by modifications at three sites of the protein structure. It binds to the fibrin component of the thrombus (blood clot) and selectively converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of the thrombus. Tenecteplase has a higher fibrin specificity and greater resistance to inactivation by its endogenous inhibitor (PAI-1) compared to native t-PA.
The revenue for Tenecteplase is expected to reach a total of $23.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tenecteplase NPV Report.
Tenecteplase (Metalyse, Tnkase) is a fibrin-specific plasminogen activator. It is formulated as powder for solution for intravenous route of administration. It is indicated in adults for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left Bundle Branch Block within 6 hours after the onset of acute myocardial infarction (AMI) symptoms.
Tenecteplase (RG-3625) is under development for the treatment of acute ischemic stroke and Coronavirus disease 2019 (COVID-19) associated with acute respiratory failure. It was also under development for the treatment of pulmonary embolism and for restoration of function in dysfunctional hemodialysis (HD) catheters and acute respiratory distress syndrome. It is administered through intraarterial route.
F. Hoffmann-La Roche Overview
F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.
The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.
Quick View – Tenecteplase
|Highest Development Stage|